TY - JOUR
T1 - Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival
AU - Pande, Mala
AU - Bondy, Melissa L.
AU - Do, Kim Anh
AU - Sahin, Aysegul A.
AU - Ying, Jun
AU - Mills, Gordon B.
AU - Thompson, Patricia A.
AU - Brewster, Abenaa M.
N1 - Funding Information:
Acknowledgments This research was supported by the following grants–Susan Komen Career Catalyst Disparities Award (AMB), Komen Foundation Promise and SAC grant (GBM), Susan G. Komen for the Cure SAC110047 and SAB0800007 (MB), National Breast Cancer Foundation, and the National Cancer Institute at the NIH SPORE P50CA116199 (MB), National Institutes of Health R01 CA089608 (MB and PT), and National Institutes of Health K07 CA160753 (MP).
Funding Information:
Conflict of interest Dr. Gordon Mills has served as a consultant for AstraZeneca, Blend, Critical Outcome Technologies, HanAl Bio Korena, Illumina, Nuevolution, Pfizer, Provista Diagnostics, Roche, Signalchem Lifesciences, Symphogen and Tau Therapeutics. He has ownership interests in Catena Pharmaceuticals, PTV Ventures, Spindle Top Ventures and has received commercial research grants from Adelson Medical Research Foundation, AstraZeneca, Critical Outcomes Technology and GlaxoSmithKline.
Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Obesity-related hormones and cytokines alter PI3 K-AKT-mTOR pathway activation in breast tumors contributing to poorer disease-free survival (DFS) and decreased responsiveness to tamoxifen and trastuzumab. We hypothesized that single nucleotide polymorphisms (SNPs) in candidate genes in the PI3 K-AKT-mTOR signaling pathway may act as genetic modifiers of breast cancer DFS. We analyzed the association of 106 tagging SNPs in 13 genes (ADIPOQ, IGF1, INS, IRS1, LEP, LEPR, LEPROT, PIK3CA, PIK3R5, PTEN, TSC1, TSC2, and AKT1) in the P13K-AKT-mTOR pathway with DFS in a sample of 1,019 women with stage I–II breast cancer. SNPs significantly associated with DFS in any genetic model (additive, dominant, or recessive) after correcting for false discovery rate (FDR = 0.10) were included in Cox proportional hazards multivariable analyses. After adjusting for race/ethnicity, age at diagnosis, tumor stage, and treatment, rs1063539 in ADIPOQ, rs11585329 in LEPR, and rs2519757 in TSC1 were associated with improved DFS, and rs1520220 in IGF1 and rs2677760 in PIK3CA were associated with worse DFS. The associations were not significantly modified by the type of systemic treatment received or body mass index. The SNPs were not associated with tumor characteristics such as tumor size, lymph node status, nuclear grade, or hormone receptor status. In this study, germline SNPs in the PI3 K-AKT-mTOR pathway were associated with breast cancer DFS and may be potential prognostic markers. Future studies are needed to replicate our results and to evaluate the relationship between these polymorphisms and activation of the PI3 K-AKT-mTOR pathway in breast tumors.
AB - Obesity-related hormones and cytokines alter PI3 K-AKT-mTOR pathway activation in breast tumors contributing to poorer disease-free survival (DFS) and decreased responsiveness to tamoxifen and trastuzumab. We hypothesized that single nucleotide polymorphisms (SNPs) in candidate genes in the PI3 K-AKT-mTOR signaling pathway may act as genetic modifiers of breast cancer DFS. We analyzed the association of 106 tagging SNPs in 13 genes (ADIPOQ, IGF1, INS, IRS1, LEP, LEPR, LEPROT, PIK3CA, PIK3R5, PTEN, TSC1, TSC2, and AKT1) in the P13K-AKT-mTOR pathway with DFS in a sample of 1,019 women with stage I–II breast cancer. SNPs significantly associated with DFS in any genetic model (additive, dominant, or recessive) after correcting for false discovery rate (FDR = 0.10) were included in Cox proportional hazards multivariable analyses. After adjusting for race/ethnicity, age at diagnosis, tumor stage, and treatment, rs1063539 in ADIPOQ, rs11585329 in LEPR, and rs2519757 in TSC1 were associated with improved DFS, and rs1520220 in IGF1 and rs2677760 in PIK3CA were associated with worse DFS. The associations were not significantly modified by the type of systemic treatment received or body mass index. The SNPs were not associated with tumor characteristics such as tumor size, lymph node status, nuclear grade, or hormone receptor status. In this study, germline SNPs in the PI3 K-AKT-mTOR pathway were associated with breast cancer DFS and may be potential prognostic markers. Future studies are needed to replicate our results and to evaluate the relationship between these polymorphisms and activation of the PI3 K-AKT-mTOR pathway in breast tumors.
KW - Breast cancer
KW - Disease-free survival
KW - PI3 K-AKT-mTOR pathway
KW - Prognosis
KW - Single nucleotide polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=84939877332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939877332&partnerID=8YFLogxK
U2 - 10.1007/s10549-014-3081-9
DO - 10.1007/s10549-014-3081-9
M3 - Article
C2 - 25108739
AN - SCOPUS:84939877332
SN - 0167-6806
VL - 147
SP - 381
EP - 387
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -